Cuprina Holdings (Cayman) Limited Class A Ordinary Shares CUPR

Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.

CUPR hizo una agrupación de acciones (split inverso) de 1:8 el 27 de mayo de 2026: cada 8 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 29 sept

  Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering

  Cuprina Holdings (Nasdaq: CUPR), a biomedical company, announced the successful closing of its underwriter's over-allotment option, selling an additional 648,373 Class A ordinary shares at $1.15 per share for approximately $745,629 in gross proceeds. Combined with the initial public offering, the company raised total aggregate gross proceeds of approximately $5.72 million, which will be used for business expansion, R&D activities, market growth, and general corporate purposes.

  

• GlobeNewswire Inc. 17 sept

  Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering

  Cuprina Holdings (Nasdaq: CUPR), a biomedical company focused on chronic wounds, infertility, medical waste recycling, and cosmeceuticals, closed its public offering of 4.32 million Class A Ordinary Shares at $1.15 per share, raising approximately $4.97 million in gross proceeds. The company plans to use net proceeds for R&D expansion, new market entry, brand building, and infrastructure investment. The offering follows FDA 510(k) clearance for MEDIFLY Maggots™ in June.

  

• Benzinga 16 jun

  Cuprina Holdings Falls 22% After 112% Rally — Here's Why CUPR Stock Is Trending

  Cuprina Holdings (NASDAQ: CUPR) surged 111.84% intraday to $8.41 after receiving FDA 510(k) clearance for MEDIFLY Maggots, a maggot debridement product for non-healing wounds. The stock subsequently fell 22.47% to $6.52 in after-hours trading. MEDIFLY Maggots is the first maggot debridement product using Lucilia cuprina species to receive FDA clearance, giving the Singapore-based biomedical company commercial rights to both maggot species used in the therapy.

  

• Benzinga 15 jun

  What's Going On With Cuprina Stock Monday?

  Cuprina Holdings (NASDAQ: CUPR) stock experienced muted trading on Monday after surging 64.73% on Friday following the company's announcement that it regained compliance with Nasdaq Capital Market listing requirements. The Singapore-based biomedical company had previously faced delisting risk due to failing to maintain a minimum bid price of $1 per share for 30 consecutive business days. With the immediate catalyst priced in, traders adopted a wait-and-see approach, with shares down 1.76% in premarket trading.